This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
SEphB4-HSA
DrugBank Accession Number
DB14797
Background

SEphB4-HSA is under investigation in clinical trial NCT02495896 (Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors).

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • RECOMBINANT EPHB4-HSA FUSION PROTEIN

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
SO0RV2V6EJ
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentALK Gene Mutation / BRAF Gene Mutation / EGFR Gene Mutations / Locally Advanced Non-Small Cell Lung Cancer / Metastatic Head and Neck Carcinoma / Recurrent Head and Neck Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / ROS1 Gene Mutation / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Stage IIIA Non Small Cell Lung Cancer / Stage IIIB Non Small Cell Lung Cancer / Stage IV Non-small Cell Lung Cancer (NSCLC)1
2Active Not RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents / Metastatic Prostate Adenocarcinoma / Progressive Disease / Prostate Carcinoma Metastatic in the Bone / Prostate Carcinoma Metastatic in the Soft Tissue / PSA Progression / Stage IVB Prostate Cancer AJCC v8 / Testosterone Less Than 50 ng/dL1
2RecruitingTreatmentKaposi's Sarcoma1
2RecruitingTreatmentMetastatic Ureter Urothelial Carcinoma1
2RecruitingTreatmentProstate Cancer / Stage IV Bladder Urothelial Carcinoma / Urothelial Carcinoma1
2RecruitingTreatmentSkin Kaposi Sarcoma1
2TerminatedTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Previously treated Myelodysplastic Syndromes (MDS) / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentNon-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Carcinoma Stage III / Recurrent Gallbladder Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Stage IIIA Gallbladder Cancer / Stage IIIA Non Small Cell Lung Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Non Small Cell Lung Cancer / Stage IV Gallbladder Cancer / Stage IV Non-small Cell Lung Cancer (NSCLC) / Stage IV Pancreatic Cancer / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Cancer1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1Not Yet RecruitingTreatmentRecurrent Bladder Carcinoma / Stage 0 Bladder Cancer / Stage I Bladder Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 14:27 / Updated at June 12, 2020 16:53